Literature DB >> 3128176

Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator.

C M Hekman1, D J Loskutoff.   

Abstract

Plasminogen activator inhibitor 1 (PAI-1) was purified from medium conditioned by cultured bovine aortic endothelial cells by successive chromatography on concanavalin A Sepharose, Sephacryl S-200, Blue B agarose, and Bio-Gel P-60. As shown previously for conditioned media (C. M. Hekman and D. J. Loskutoff (1985) J. Biol. Chem. 260, 11581-11587) the purified PAI-1 preparation contained latent inhibitory activity which could be stimulated 9.4-fold by sodium dodecyl sulfate and 45-fold by guanidine-HCl. The specific activity of the preparation following treatment with 0.1% sodium dodecyl sulfate was 2.5 X 10(3) IU/mg. The reaction between purified, guanidine-activated PAI-1 and both urokinase and tissue plasminogen activator (tPA) was studied. The second-order rate constants (pH 7.2, 35 degrees C) for the interaction between guanidine-activated PAI-1 and urokinase (UK), and one- and two-chain tPA are 1.6 X 10(8), 4.0 X 10(7), and 1.5 X 10(8) M-1 S-1, respectively. The presence of CNBr fibrinogen fragments had no affect on the rate constants of either one- or two-chain tPA. Steady-state kinetic analysis of the effect of PAI-1 on the rate of plasminogen activation revealed that the initial UK/PAI-1 interaction can be competed with plasminogen suggesting that the UK/PAI-1 interaction may involve a competitive type of inhibition. In contrast, the initial tPA/PAI-1 interaction can be competed only partially with plasminogen, suggesting that the tPA/PAI-1 interaction may involve a mixed type of inhibition. The results indicate that PAI-1 interacts more rapidly with UK and tPA than any PAI reported to date and suggest that PAI-1 is the primary physiological inhibitor of single-chain tPA. Moreover, the interaction of PAI-1 with tPA differs from its interaction with UK, and may involve two sites on the tPA molecule.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128176     DOI: 10.1016/0003-9861(88)90182-8

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  21 in total

1.  Active α-macroglobulin is a reservoir for urokinase after fibrinolytic therapy in rabbits with tetracycline-induced pleural injury and in human pleural fluids.

Authors:  Andrey A Komissarov; Galina Florova; Ali Azghani; Sophia Karandashova; Anna K Kurdowska; Steven Idell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-08-30       Impact factor: 5.464

2.  Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1.

Authors:  E L Madison; E J Goldsmith; R D Gerard; M J Gething; J F Sambrook; R S Bassel-Duby
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

3.  The cluster of basic amino acids in vitronectin contributes to its binding of plasminogen activator inhibitor-1: evidence from thrombin-, elastase- and plasmin-cleaved vitronectins and anti-peptide antibodies.

Authors:  Z Gechtman; A Belleli; S Lechpammer; S Shaltiel
Journal:  Biochem J       Date:  1997-07-15       Impact factor: 3.857

4.  Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.

Authors:  O F Wagner; C de Vries; C Hohmann; H Veerman; H Pannekoek
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

5.  Changes in tissue-plasminogen activator mRNA expression following cortical ablation in the rat brain.

Authors:  E Kohmura; T Yuguchi; T Sakaki; M Nonaka; T Fujinaka; T Hayakawa; T Yoshimine
Journal:  J Mol Neurosci       Date:  2000 Feb-Apr       Impact factor: 3.444

6.  Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.

Authors:  J D Sipley; D S Alexander; J E Testa; J P Quigley
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

7.  Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.

Authors:  Galina Florova; Ali O Azghani; Sophia Karandashova; Chris Schaefer; Serge V Yarovoi; Paul J Declerck; Douglas B Cines; Steven Idell; Andrey A Komissarov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

8.  Effects of energy intake on type 1 plasminogen activator inhibitor levels in glomeruli of lupus-prone B/W mice.

Authors:  D A Troyer; B Chandrasekar; T Thinnes; A Stone; D J Loskutoff; G Fernandes
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

9.  Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.

Authors:  M S Sawdey; D J Loskutoff
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

10.  Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.

Authors:  R R Schleef; D L Higgins; E Pillemer; L J Levitt
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.